Wanda Graupman, NP
Family · Trenton, TNNPI 1326406372
Payments from drug & device makers
Across 440 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$750
- Pfizer$583
- Lilly USA, LLC$493
- Bayer$354
- Amgen$313
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,557100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 99 | $1,240 |
| Novo Nordisk | 42 | $750 |
| Pfizer | 42 | $583 |
| Lilly USA, LLC | 45 | $493 |
| Bayer | 22 | $354 |
| Amgen | 24 | $313 |
| Otsuka America Pharmaceutical, Inc. | 20 | $288 |
| Lundbeck LLC | 15 | $284 |
| Merck | 18 | $280 |
| Biohaven Pharmaceuticals, Inc. | 14 | $247 |
| Mylan Specialty L.p. | 13 | $245 |
| AstraZeneca | 16 | $228 |
| GSK | 10 | $180 |
| Exact Sciences | 5 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| Phathom Pharmaceuticals, Inc. | 5 | $84 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $71 |
| Johnson & Johnson | 4 | $60 |
| Corium, LLC | 4 | $57 |
| Dexcom, Inc. | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 3 | $42 |
| Abbott | 2 | $42 |
| Eisai Inc. | 2 | $37 |
| Medtronic | 1 | $34 |
| Astellas Pharma US Inc | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Novartis | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$6,557 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $121,700 |
| MounjaroTirzepatide | 38 | $44,020 |
| JardianceEmpagliflozin | 36 | $37,568 |
| TrulicityDulaglutide | 23 | $34,040 |
| VraylarCariprazine Hcl | 23 | $33,741 |
| EliquisApixaban | 26 | $29,489 |
| FarxigaDapagliflozin Propanediol | 42 | $29,349 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $25,381 |
| CaplytaLumateperone Tosylate | 12 | $23,094 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $21,380 |
| LinzessLinaclotide | 21 | $19,198 |
| Repatha SureclickEvolocumab | 15 | $17,477 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $13,670 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $12,432 |
| MyrbetriqMirabegron | 18 | $12,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $750 | $121,700107 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $493 | $80,47273 claims |
| AbbVieVraylar, Linzess | $1,240 | $52,93944 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $228 | $50,72861 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $31,72543 claims |
| PfizerEliquis | $583 | $29,48926 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $71 | $23,09412 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $12,39118 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $11,54016 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $79 | $9,74613 claims |
| MerckJanumet Xr | $280 | $7,65812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Trenton
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.